Literature DB >> 29377345

Structural insights into Resolvin D4 actions and further metabolites via a new total organic synthesis and validation.

Jeremy W Winkler1, Stephania Libreros1, Xavier De La Rosa1, Brian E Sansbury1, Paul C Norris1, Nan Chiang1, David Fichtner2, Gregory S Keyes2, Nicholas Wourms2, Matthew Spite1, Charles N Serhan1.   

Abstract

Local production and downstream metabolism of specialized proresolving lipid mediators (SPMs) are pivotal in regulating their biological actions during resolution of inflammation. Resolvin D4 (RvD4: 4S,5R,17S-trihydroxydocosa-6E,8E,10Z,13Z,15E,19Z hexaenoic acid) is one of the more recently elucidated SPMs with complete stereochemistry biosynthesized from docosahexaenoic acid . Here, we report a new multimilligram commercial synthesis that afforded enough material for matching, validation, and further evaluation of RvD4 functions. Using LC-MS-MS profiling, RvD4 was identified at bioactive amounts in human (1 pg/mL) and mouse bone marrow (12 pg/femur and tibia). In mouse bone marrow, ischemia increased the formation of RvD4 > 37-fold (455 pg/femur and tibia). Two separate mouse ischemic injury models were used, where RvD4 reduced second organ reperfusion lung injury > 50%, demonstrating organ protection. Structure-function relationships of RvD4 demonstrated > 40% increase in neutrophil and monocyte phagocytic function in human whole blood in comparison with 2 separate trans-containing double bond isomers that were inactive. These 2 isomers were prepared by organic synthesis: 4S,5R,17S-trihydroxydocosa-6E,8E,10E,13Z,15E,19Z-hexaenoic acid (10-trans-RvD4), a natural isomer, and 4S,5R,17S-trihydroxydocosa-6E,8E,10E,13E,15E,19Z-hexaenoic acid (10,13-trans-RvD4), a rogue isomer. Compared to leukotriene B4 , D-series resolvins (RvD1, RvD2, RvD3, RvD4, or RvD5) did not stimulate human neutrophil chemotaxis monitored via real-time microfluidics chambers. A novel 17-oxo-containing-RvD4 product of eicosanoid oxidoreductase was identified with human bone marrow cells. Comparison of 17-oxo-RvD4 to RvD4 demonstrated that with human leukocytes 17-oxo-RvD4 was inactive. Together, these provide commercial-scale synthesis that permitted a second independent validation of RvD4 complete stereochemical structure as well as evidence for RvD4 regulation in tissues and its stereoselective phagocyte responses. ©2018 Society for Leukocyte Biology.

Entities:  

Keywords:  anti-inflammatory; essential fatty acids; ischemia; leukocytes; oxidoreductase; reperfusion injury; resolvins; specialized proresolving mediators

Year:  2018        PMID: 29377345      PMCID: PMC6136982          DOI: 10.1002/JLB.3MI0617-254R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  34 in total

1.  Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents.

Authors:  Jesmond Dalli; Jeremy W Winkler; Romain A Colas; Hildur Arnardottir; Chien-Yee C Cheng; Nan Chiang; Nicos A Petasis; Charles N Serhan
Journal:  Chem Biol       Date:  2013-02-21

2.  IMP and AMP deaminase in reperfusion injury down-regulates neutrophil recruitment.

Authors:  F H Qiu; K Wada; G L Stahl; C N Serhan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

3.  Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat.

Authors:  Joan Clària; Jesmond Dalli; Stephanie Yacoubian; Fei Gao; Charles N Serhan
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

4.  Resolvin D2 Enhances Postischemic Revascularization While Resolving Inflammation.

Authors:  Michael J Zhang; Brian E Sansbury; Jason Hellmann; James F Baker; Luping Guo; Caitlin M Parmer; Joshua C Prenner; Daniel J Conklin; Aruni Bhatnagar; Mark A Creager; Matthew Spite
Journal:  Circulation       Date:  2016-08-09       Impact factor: 29.690

Review 5.  Pro-resolving lipid mediators are leads for resolution physiology.

Authors:  Charles N Serhan
Journal:  Nature       Date:  2014-06-05       Impact factor: 49.962

Review 6.  Anti-inflammatory therapy in chronic disease: challenges and opportunities.

Authors:  Ira Tabas; Christopher K Glass
Journal:  Science       Date:  2013-01-11       Impact factor: 47.728

7.  Infection regulates pro-resolving mediators that lower antibiotic requirements.

Authors:  Nan Chiang; Gabrielle Fredman; Fredrik Bäckhed; Sungwhan F Oh; Thad Vickery; Birgitta A Schmidt; Charles N Serhan
Journal:  Nature       Date:  2012-04-25       Impact factor: 49.962

8.  Mass spectrometry imaging of biomarker lipids for phagocytosis and signalling during focal cerebral ischaemia.

Authors:  Mette M B Nielsen; Kate L Lambertsen; Bettina H Clausen; Morten Meyer; Dhaka R Bhandari; Søren T Larsen; Steen S Poulsen; Bernhard Spengler; Christian Janfelt; Harald S Hansen
Journal:  Sci Rep       Date:  2016-12-22       Impact factor: 4.379

9.  Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis.

Authors:  Matthew Spite; Lucy V Norling; Lisa Summers; Rong Yang; Dianne Cooper; Nicos A Petasis; Roderick J Flower; Mauro Perretti; Charles N Serhan
Journal:  Nature       Date:  2009-10-29       Impact factor: 49.962

Review 10.  Proresolving lipid mediators and mechanisms in the resolution of acute inflammation.

Authors:  Christopher D Buckley; Derek W Gilroy; Charles N Serhan
Journal:  Immunity       Date:  2014-03-20       Impact factor: 31.745

View more
  13 in total

1.  Identification of Chemotype Agonists for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions.

Authors:  Nan Chiang; Elena Barnaeva; Xin Hu; Juan Marugan; Noel Southall; Marc Ferrer; Charles N Serhan
Journal:  Cell Chem Biol       Date:  2018-12-13       Impact factor: 8.116

Review 2.  Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.

Authors:  Charles N Serhan; Bruce D Levy
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 3.  Specialized pro-resolving mediator network: an update on production and actions.

Authors:  Nan Chiang; Charles N Serhan
Journal:  Essays Biochem       Date:  2020-09-23       Impact factor: 8.000

4.  Resolvin D4 attenuates the severity of pathological thrombosis in mice.

Authors:  Deya Cherpokova; Charlotte C Jouvene; Stephania Libreros; Elise P DeRoo; Long Chu; Xavier de la Rosa; Paul C Norris; Denisa D Wagner; Charles N Serhan
Journal:  Blood       Date:  2019-10-24       Impact factor: 22.113

5.  Human leukocytes selectively convert 4S,5S-epoxy-resolvin to resolvin D3, resolvin D4, and a cys-resolvin isomer.

Authors:  Ashley E Shay; Robert Nshimiyimana; Bengt Samuelsson; Nicos A Petasis; Jesper Z Haeggström; Charles N Serhan
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-21       Impact factor: 12.779

6.  Cutting Edge: Human Vagus Produces Specialized Proresolving Mediators of Inflammation with Electrical Stimulation Reducing Proinflammatory Eicosanoids.

Authors:  Charles N Serhan; Xavier de la Rosa; Charlotte C Jouvene
Journal:  J Immunol       Date:  2018-10-24       Impact factor: 5.422

7.  Commercial scale production of RvD4 opens the resolving door to new research.

Authors:  Matthew L Edin; Darryl C Zeldin
Journal:  J Leukoc Biol       Date:  2018-03-30       Impact factor: 4.962

8.  Myeloid ALX/FPR2 regulates vascularization following tissue injury.

Authors:  Brian E Sansbury; Xiaofeng Li; Blenda Wong; Andreas Patsalos; Nikolas Giannakis; Michael J Zhang; Laszlo Nagy; Matthew Spite
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-08       Impact factor: 11.205

Review 9.  Pro-Resolving Ligands Orchestrate Phagocytosis.

Authors:  Christa Decker; Sudeshna Sadhu; Gabrielle Fredman
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

10.  Distinct Analgesic Actions of DHA and DHA-Derived Specialized Pro-Resolving Mediators on Post-operative Pain After Bone Fracture in Mice.

Authors:  Linlin Zhang; Niccolò Terrando; Zhen-Zhong Xu; Sangsu Bang; Sven-Eric Jordt; William Maixner; Charles N Serhan; Ru-Rong Ji
Journal:  Front Pharmacol       Date:  2018-05-01       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.